Foresight Diagnostics Patent Issued for Minimal Residual Disease Detection Technology

AURORA, Colo., Sept. 27, 2022 /PRNewswire/ — Foresight Diagnostics, Inc, a leader in cancer diagnostics and cancer relapse testing, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the company patent No.11,447,833 for the detection of minimal residual disease…

Click here to view original post